Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260

Benzinga Newsdesk www.benzinga.com Positive 92.1%

Neg 0% Neu 0% Pos 92.1%

Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $235 to $260.